Frunevetmab

Frunevetmab
Monoclonal antibody
Type	Whole antibody
Source	Rat
Target	Nerve growth factor (NGF)
Clinical data
Trade names	Solensia
License data	US DailyMed: Frunevetmab;
Routes of; administration	Subcutaneous
ATCvet code	QN02BG90 (WHO) ;
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Identifiers
CAS Number	1708936-80-4;
UNII	77O28MCS79;
KEGG	D10935;

Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.^[2]

The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis and pruritus (itchy skin).^[2]

Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.^[2] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.^[2]

Frunevetmab was approved for medical use in the European Union in February 2021,^[3] and in the United States in January 2022.^[2]^[4] It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.^[2]

Medical uses[]

Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.^[2]^[3]

Society and culture[]

Names[]

Frunevetmab is the international nonproprietary name (INN).^[5]

References[]

^ https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817^{[bare URL PDF]}
^ ^a ^b ^c ^d ^e ^f ^g ^h "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Retrieved 14 January 2022. This article incorporates text from this source, which is in the public domain.
^ ^a ^b ^c "Solensia EPAR". European Medicines Agency (EMA). Retrieved 14 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats". Zoetis. 13 January 2022. Retrieved 14 January 2022.
^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

This article incorporates public domain material from the United States Department of Health and Human Services website https://www.fda.gov/.

External links[]

"Frunevetmab". Drug Information Portal. U.S. National Library of Medicine.

This veterinary medicine–related article is a stub. You can help Wikipedia by .

[1] ttps://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817^{[bare URL PDF]}

[FDA_PR_20220113-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Retrieved 14 January 2022. This article incorporates text from this source, which is in the public domain.

[Solensia_EPAR-3] "Solensia EPAR". European Medicines Agency (EMA). Retrieved 14 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[4] "Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats". Zoetis. 13 January 2022. Retrieved 14 January 2022.

[WHORecList78-5] World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

[1]

[2]

[3]

[4]

[5]